Details of the Drug Combinations

General Information of This Drug (ID: DMSQLZJ)

Drug Name

Nifurtimox DMSQLZJ

Synonyms

NIFURTIMOX; Lampit; Bayer 2502; 23256-30-6; BAY 2502; Nifurtimox [INN:BAN]; Nifurtimoxum [INN-Latin]; CCRIS 2201; EINECS 245-531-0; CHEBI:7566; C10H13N3O5S; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide; 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide; 3-Methyl-N-[(5-nitro-2-furanyl)methylene]-4-thiomorpholinamine 1,1-dioxide; 3-Methyl-4-(5'-nitrofurylidene-amino)-tetrahydro-4H-1,4-thiazine-1,1-dioxide

Indication

Disease Entry	ICD 11	Status	REF
Chagas disease	IF53	Approved	[1]
Trypanosomiasis	1D51-1F53	Phase 4	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Eflornithine + Nifurtimox	DCQDAKR	Eflornithine	Human African Trypanosomiasis (HAT)	[3]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2	ClinicalTrials.gov (NCT00906880) Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense HumanAfrican Trypanosomiasis (HAT) in the Meningo-encephalitic Phase. U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT01685827) Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2